Research Shows Majority Of Insured People With Type 2 Diabetes Supplement Their Prescribed Number Of BGM Test Strips And Overestimate The Cost

PARSIPPANY, N.J., May 27, 2021 /PRNewswire/ -- People living with type 2 diabetes in the US may not be being prescribed enough blood glucose monitoring (BGM) test strips to help them optimally manage their diabetes, according to new research from Ascensia Diabetes Care, a leading diabetes care company and makers of CONTOUR® NEXT BGM and test strips. Additionally, the research shows that people with diabetes are overestimating the real price of test strips purchased over-the-counter (OTC), with the average price estimate at almost four times as much as the real cost^1,2.

There are approximately 12 million people with type 2 diabetes in the US who use a BGM to monitor their condition³. Ascensia's recent survey of more than 750 people living with type 2 diabetes in the US found that, among those with health insurance, over half (54%) are topping up their prescriptions of test strips at least once a month by purchasing additional ones OTC and 79% do so least every two to three months, suggesting that they are either not prescribed enough or are underinsured.

Mary Puncochar, Head of US Region, at Ascensia Diabetes Care commented: "While there is a stronger rationale for blood glucose monitoring in people with type 2 diabetes who are using insulin, we believe it is genuinely valuable for everyone with type 2 diabetes, as it enables them to see how their blood glucose levels react to food, medication and exercise. With such a large percentage of people topping up their prescribed allocation of BGM test strips, our research indicates that many people with type 2 diabetes would like to monitor more regularly than their insurance allows for, suggesting they see a benefit in having more information about their blood glucose levels to help them manage their diabetes."

The research also showed a lack of awareness about the real cost of test strips when purchased over-the-counter. On average, survey respondents with insurance expect each test strip to cost $1.69. However, in actuality, the average cost³ is approximately between 40 and 70 cents per strip, dependent on brand and where the purchase is made.

Mary Puncochar, at Ascensia Diabetes Care continued: "Diabetes is an expensive life-long condition and managing the way through the maze of healthcare costs can be confusing for people. Being aware of the real cost empowers the consumer, enabling them to make an informed decision about the best way to pay for crucial diabetes supplies they need to help them manage their condition. Our research suggests that people are significantly overestimating the cost of purchasing test strips out of pocket, thinking it could be up to four times as much. For those with insurance that has a high co-pay, there might be times when cash or out-of-pocket could be the cheaper option for them."

For more information and to access tools that can help assess the most cost effective option for obtaining test strips, please visit www.ascensiadiabetes.com/otc

1. Ascensia Diabetes Care. Data on file. BGM Test Strips - Cash Research. January 2021 2. Ascensia Diabetes Care. Data on File. BGM Diagnosed Patients - CDC. January 2021 3. Ascensia Diabetes Care. Data on file. Current OTC BGM Test Strip Pricing. April 2021

Notes for Editors

About Ascensia Diabetes Care

Ascensia Diabetes Care is a global company focused entirely on helping people with diabetes. Our mission is to empower those living with diabetes through innovative solutions that simplify and improve their lives.

We are home to the world renowned CONTOUR^® portfolio of blood glucose monitoring systems and the exclusive global distribution partner for the Eversense^® continuous glucose monitoring systems from Senseonics. These products combine advanced technology with user-friendly functionality to help people with diabetes manage their condition and make a positive difference to their lives. As a trusted partner in the diabetes community, we collaborate closely with healthcare professionals and other partners to ensure our products meet the highest standards of accuracy, precision and reliability, and that we conduct our business compliantly and with integrity.

Ascensia is a member of the PHC Group and was established in 2016 through the sale of Bayer Diabetes Care to PHC Holdings (formerly Panasonic Healthcare). Ascensia products are sold in more than 125 countries. Ascensia has around 1,700 employees and operations in 31 countries.

For further information, please visit the Ascensia Diabetes Care website at: http://www.ascensia.com.

©2021 Ascensia Diabetes Care Holdings AG. All right reserved. Ascensia, the Ascensia Diabetes Care logo and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG.

SOURCE Ascensia Diabetes Care

Related Links

http://www.ascensia.com